127 related articles for article (PubMed ID: 29304474)
21. Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.
Capone E; Piccolo E; Fichera I; Ciufici P; Barcaroli D; Sala A; De Laurenzi V; Iacobelli V; Iacobelli S; Sala G
Oncotarget; 2017 Sep; 8(36):60368-60377. PubMed ID: 28947977
[TBL] [Abstract][Full Text] [Related]
22. Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.
Chacko AM; Li C; Nayak M; Mikitsh JL; Hu J; Hou C; Grasso L; Nicolaides NC; Muzykantov VR; Divgi CR; Coukos G
J Nucl Med; 2014 Mar; 55(3):500-507. PubMed ID: 24525208
[TBL] [Abstract][Full Text] [Related]
23. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
24. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
25. Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells.
Thway K; Robertson D; Jones RL; Selfe J; Shipley J; Fisher C; Isacke CM
Br J Cancer; 2016 Aug; 115(4):473-9. PubMed ID: 27434038
[TBL] [Abstract][Full Text] [Related]
26. Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248.
Bagley RG; Rouleau C; St Martin T; Boutin P; Weber W; Ruzek M; Honma N; Nacht M; Shankara S; Kataoka S; Ishida I; Roberts BL; Teicher BA
Mol Cancer Ther; 2008 Aug; 7(8):2536-46. PubMed ID: 18723498
[TBL] [Abstract][Full Text] [Related]
27. Tumor Endothelial Marker 1 (TEM1/Endosialin/CD248) Enhances Wound Healing by Interacting with Platelet-Derived Growth Factor Receptors.
Hong YK; Lee YC; Cheng TL; Lai CH; Hsu CK; Kuo CH; Hsu YY; Li JT; Chang BI; Ma CY; Lin SW; Wang KC; Shi GY; Wu HL
J Invest Dermatol; 2019 Oct; 139(10):2204-2214.e7. PubMed ID: 30986375
[TBL] [Abstract][Full Text] [Related]
28. Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity.
Stratford EW; Bostad M; Castro R; Skarpen E; Berg K; Høgset A; Myklebost O; Selbo PK
Biochim Biophys Acta; 2013 Aug; 1830(8):4235-43. PubMed ID: 23643966
[TBL] [Abstract][Full Text] [Related]
29. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells.
Christian S; Winkler R; Helfrich I; Boos AM; Besemfelder E; Schadendorf D; Augustin HG
Am J Pathol; 2008 Feb; 172(2):486-94. PubMed ID: 18187565
[TBL] [Abstract][Full Text] [Related]
30. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
31. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy.
Marty C; Langer-Machova Z; Sigrist S; Schott H; Schwendener RA; Ballmer-Hofer K
Cancer Lett; 2006 Apr; 235(2):298-308. PubMed ID: 15953677
[TBL] [Abstract][Full Text] [Related]
32. Phage display-based on-slide selection of tumor-specific antibodies on formalin-fixed paraffin-embedded human tissue biopsies.
Ten Haaf A; Pscherer S; Fries K; Barth S; Gattenlöhner S; Tur MK
Immunol Lett; 2015 Aug; 166(2):65-78. PubMed ID: 26045318
[TBL] [Abstract][Full Text] [Related]
33. Endosialin: a novel malignant cell therapeutic target for neuroblastoma.
Rouleau C; Smale R; Sancho J; Fu YS; Kurtzberg L; Weber W; Kruger A; Jones C; Roth S; Bormann C; Dunham S; Krumbholz R; Curiel M; Wallar G; Mascarello J; Campos-Rivera J; Horten B; Schmid S; Miller G; Teicher BA
Int J Oncol; 2011 Oct; 39(4):841-51. PubMed ID: 21701770
[TBL] [Abstract][Full Text] [Related]
34. CD248: A therapeutic target in cancer and fibrotic diseases.
Teicher BA
Oncotarget; 2019 Jan; 10(9):993-1009. PubMed ID: 30847027
[TBL] [Abstract][Full Text] [Related]
35. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium.
MacFadyen JR; Haworth O; Roberston D; Hardie D; Webster MT; Morris HR; Panico M; Sutton-Smith M; Dell A; van der Geer P; Wienke D; Buckley CD; Isacke CM
FEBS Lett; 2005 May; 579(12):2569-75. PubMed ID: 15862292
[TBL] [Abstract][Full Text] [Related]
36. TEM1 up-regulates MMP-2 and promotes ECM remodeling for facilitating invasion and migration of uterine sarcoma.
Wu C; Sun W; Shen D; Li H; Tong X; Guo Y
Discov Oncol; 2023 Jan; 14(1):5. PubMed ID: 36639546
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
38. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors.
Nanda A; Karim B; Peng Z; Liu G; Qiu W; Gan C; Vogelstein B; St Croix B; Kinzler KW; Huso DL
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3351-6. PubMed ID: 16492758
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo efficacy of heat shock protein specific immunotoxins on human tumor cells.
Piselli P; Vendetti S; Poccia F; Cicconi R; Mattei M; Bolognesi A; Stirpe F; Colizzi V
J Biol Regul Homeost Agents; 1995; 9(2):55-62. PubMed ID: 9127634
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.
Muñoz R; Arias Y; Ferreras JM; Jiménez P; Langa C; Rojo MA; Gayoso MJ; Córdoba-Díaz D; Bernabéu C; Girbés T
Cancer Immunol Immunother; 2013 Mar; 62(3):541-51. PubMed ID: 23076642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
